Monday, 3 July 2017

The Hematologic Toxicity of Methotrexate in Patients with Autoimmune Disorders

The incidence of autoimmune diseases increased to the end of twenty centuries. Despite of the development of diagnosis and therapy in medicine, autoimmune diseases remainedincurable.

Autoimmune Disorders
Only long-term treatment with harmful agents is available for these patients, such as methotrexate or other immuno-suppressive drugs. Methotrexate, a synthetic antifolate was developed in the 1950’s after the discovery that dietary folic acid deficiency resulted in decreased blast cell count in leukemic patients. This drug has been extensively investigated and used successfully to treat solid tumors as well as hematological malignancies. It has been used, in much lower doses, in autoimmune diseases including rheumatoid arthritis, psoriasis, lupus, sarcoidosis, and eczema. By inhibiting several enzymes of the folic acid pathway MTX blocks purine and pyrimidine biosynthesis, leading to impaired DNA replication and cell proliferation.


No comments:

Post a Comment